pbs_code
stringlengths 5
6
| drug
stringclasses 17
values | brand
stringclasses 30
values | formulation
stringclasses 37
values | indication
stringclasses 8
values | treatment_phase
stringclasses 57
values | streamlined_code
stringclasses 33
values | online_application
bool 2
classes | authority_method
stringclasses 2
values | hospital_type
stringclasses 3
values | schedule_code
int64 3.57k
3.57k
| schedule_year
int64 2.03k
2.03k
| schedule_month
stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
9658H | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 3,571 | 2,025 | FEBRUARY |
9658H | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Public | 3,571 | 2,025 | FEBRUARY |
9658H | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Public | 3,571 | 2,025 | FEBRUARY |
9658H | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Public | 3,571 | 2,025 | FEBRUARY |
9658H | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 3,571 | 2,025 | FEBRUARY |
10897M | certolizumab pegol | Cimzia | Injection 200 mg in 1 mL single use pre-filled syringe | ankylosing spondylitis | Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
5757B | infliximab | Renflexis | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Public | 3,571 | 2,025 | FEBRUARY |
5757B | infliximab | Remicade | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Public | 3,571 | 2,025 | FEBRUARY |
5757B | infliximab | Inflectra | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Public | 3,571 | 2,025 | FEBRUARY |
5757B | infliximab | Renflexis | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 3,571 | 2,025 | FEBRUARY |
5757B | infliximab | Remicade | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 3,571 | 2,025 | FEBRUARY |
5757B | infliximab | Inflectra | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 3,571 | 2,025 | FEBRUARY |
5757B | infliximab | Renflexis | Powder for I.V. infusion 100 mg | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Public | 3,571 | 2,025 | FEBRUARY |
5757B | infliximab | Remicade | Powder for I.V. infusion 100 mg | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Public | 3,571 | 2,025 | FEBRUARY |
5757B | infliximab | Inflectra | Powder for I.V. infusion 100 mg | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Public | 3,571 | 2,025 | FEBRUARY |
5757B | infliximab | Renflexis | Powder for I.V. infusion 100 mg | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 3,571 | 2,025 | FEBRUARY |
5757B | infliximab | Remicade | Powder for I.V. infusion 100 mg | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 3,571 | 2,025 | FEBRUARY |
5757B | infliximab | Inflectra | Powder for I.V. infusion 100 mg | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 3,571 | 2,025 | FEBRUARY |
5757B | infliximab | Renflexis | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Public | 3,571 | 2,025 | FEBRUARY |
5757B | infliximab | Remicade | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Public | 3,571 | 2,025 | FEBRUARY |
5757B | infliximab | Inflectra | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Public | 3,571 | 2,025 | FEBRUARY |
5757B | infliximab | Renflexis | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Public | 3,571 | 2,025 | FEBRUARY |
5757B | infliximab | Remicade | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Public | 3,571 | 2,025 | FEBRUARY |
5757B | infliximab | Inflectra | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Public | 3,571 | 2,025 | FEBRUARY |
13048R | infliximab | Remsima SC | Solution for injection 120 mg in 1 mL pre-filled pen | ankylosing spondylitis | Continuing treatment with subcutaneous form or switching from intravenous form to subcutaneous form | null | true | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
13715W | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | rheumatoid arthritis | Subsequent continuing treatment | 14621 | true | STREAMLINED | Public | 3,571 | 2,025 | FEBRUARY |
13056E | infliximab | Remsima SC | Solution for injection 120 mg in 1 mL pre-filled pen | psoriatic arthritis | Balance of supply (including switching formulation) where the full duration of treatment available under a particular treatment phase was not requested in the preceding prescription | null | true | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
13311N | tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | juvenile idiopathic arthritis | Continuing treatment | 14082 | true | STREAMLINED | Private | 3,571 | 2,025 | FEBRUARY |
9090K | etanercept | Enbrel | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
9090K | etanercept | Brenzys | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
9090K | etanercept | Enbrel | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
9090K | etanercept | Brenzys | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
13735X | certolizumab pegol | Cimzia | Injection 200 mg in 1 mL single use pre-filled syringe | rheumatoid arthritis | Subsequent continuing treatment | 14499 | true | STREAMLINED | Any | 3,571 | 2,025 | FEBRUARY |
12396K | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 3,571 | 2,025 | FEBRUARY |
12396K | adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 3,571 | 2,025 | FEBRUARY |
12396K | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 3,571 | 2,025 | FEBRUARY |
12396K | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 3,571 | 2,025 | FEBRUARY |
12396K | adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 3,571 | 2,025 | FEBRUARY |
12396K | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 3,571 | 2,025 | FEBRUARY |
12396K | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 3,571 | 2,025 | FEBRUARY |
12396K | adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 3,571 | 2,025 | FEBRUARY |
12396K | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 3,571 | 2,025 | FEBRUARY |
12396K | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 3,571 | 2,025 | FEBRUARY |
12396K | adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 3,571 | 2,025 | FEBRUARY |
12396K | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 3,571 | 2,025 | FEBRUARY |
12566J | infliximab | Remsima SC | Solution for injection 120 mg in 1 mL pre-filled pen | rheumatoid arthritis | Balance of supply for Initial treatment, Continuing treatment - subcutaneous form | null | true | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
11324B | certolizumab pegol | Cimzia | Solution for injection 200 mg in 1 mL pre-filled pen | psoriatic arthritis | Continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
11324B | certolizumab pegol | Cimzia | Solution for injection 200 mg in 1 mL pre-filled pen | psoriatic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
9457R | etanercept | Enbrel | Injection 50 mg in 1 mL single use auto-injector, 4 | psoriatic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
9457R | etanercept | Brenzys | Injection 50 mg in 1 mL single use auto-injector, 4 | psoriatic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
9457R | etanercept | Enbrel | Injection 50 mg in 1 mL single use auto-injector, 4 | psoriatic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
9457R | etanercept | Brenzys | Injection 50 mg in 1 mL single use auto-injector, 4 | psoriatic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
9457R | etanercept | Enbrel | Injection 50 mg in 1 mL single use auto-injector, 4 | psoriatic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
9457R | etanercept | Brenzys | Injection 50 mg in 1 mL single use auto-injector, 4 | psoriatic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
9457R | etanercept | Enbrel | Injection 50 mg in 1 mL single use auto-injector, 4 | psoriatic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
9457R | etanercept | Brenzys | Injection 50 mg in 1 mL single use auto-injector, 4 | psoriatic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
9458T | etanercept | Enbrel | Injection 50 mg in 1 mL single use auto-injector, 4 | psoriatic arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
9458T | etanercept | Brenzys | Injection 50 mg in 1 mL single use auto-injector, 4 | psoriatic arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
9458T | etanercept | Enbrel | Injection 50 mg in 1 mL single use auto-injector, 4 | psoriatic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
9458T | etanercept | Brenzys | Injection 50 mg in 1 mL single use auto-injector, 4 | psoriatic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
10511F | tofacitinib | Xeljanz | Tablet 5 mg | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
10511F | tofacitinib | Xeljanz | Tablet 5 mg | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
13229G | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Continuing treatment | 14107 | true | STREAMLINED | Private | 3,571 | 2,025 | FEBRUARY |
13229G | adalimumab | Hyrimoz | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Continuing treatment | 14107 | true | STREAMLINED | Private | 3,571 | 2,025 | FEBRUARY |
13229G | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Continuing treatment | 14107 | true | STREAMLINED | Private | 3,571 | 2,025 | FEBRUARY |
13229G | adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Continuing treatment | 14107 | true | STREAMLINED | Private | 3,571 | 2,025 | FEBRUARY |
13229G | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Continuing treatment | 14107 | true | STREAMLINED | Private | 3,571 | 2,025 | FEBRUARY |
10064Q | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 3,571 | 2,025 | FEBRUARY |
10064Q | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Public | 3,571 | 2,025 | FEBRUARY |
10064Q | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 3,571 | 2,025 | FEBRUARY |
10064Q | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 3,571 | 2,025 | FEBRUARY |
13338B | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Continuing treatment | 14082 | true | STREAMLINED | Private | 3,571 | 2,025 | FEBRUARY |
12763R | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | rheumatoid arthritis | Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab) | null | true | AUTHORITY_REQUIRED | Public | 3,571 | 2,025 | FEBRUARY |
11521J | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled pen | non-radiographic axial spondyloarthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
11521J | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled pen | non-radiographic axial spondyloarthritis | Continuing treatment | null | true | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
5735W | etanercept | Enbrel | Injection 50 mg in 1 mL single use auto-injector, 4 | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 3,571 | 2,025 | FEBRUARY |
5735W | etanercept | Enbrel | Injection 50 mg in 1 mL single use auto-injector, 4 | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 3,571 | 2,025 | FEBRUARY |
5735W | etanercept | Enbrel | Injection 50 mg in 1 mL single use auto-injector, 4 | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Public | 3,571 | 2,025 | FEBRUARY |
5735W | etanercept | Enbrel | Injection 50 mg in 1 mL single use auto-injector, 4 | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 3,571 | 2,025 | FEBRUARY |
12554R | infliximab | Remsima SC | Solution for injection 120 mg in 1 mL pre-filled pen | rheumatoid arthritis | Continuing treatment with subcutaneous form or switching from intravenous form to subcutaneous form | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
9088H | etanercept | Brenzys | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | psoriatic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
9088H | etanercept | Enbrel | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | psoriatic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
9088H | etanercept | Brenzys | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | psoriatic arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
9088H | etanercept | Enbrel | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | psoriatic arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
10072D | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 3,571 | 2,025 | FEBRUARY |
10072D | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Public | 3,571 | 2,025 | FEBRUARY |
10072D | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Continuing Treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 3,571 | 2,025 | FEBRUARY |
10072D | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Continuing treatment | null | false | AUTHORITY_REQUIRED | Public | 3,571 | 2,025 | FEBRUARY |
10072D | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Public | 3,571 | 2,025 | FEBRUARY |
10072D | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Public | 3,571 | 2,025 | FEBRUARY |
12321L | secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | non-radiographic axial spondyloarthritis | Initial treatment - Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years) | null | true | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
12321L | secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | non-radiographic axial spondyloarthritis | Initial treatment - Initial 2 (Change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | true | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
12321L | secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | non-radiographic axial spondyloarthritis | Initial treatment - Initial 1 (New patient) | null | false | AUTHORITY_REQUIRED | Any | 3,571 | 2,025 | FEBRUARY |
13685G | tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | rheumatoid arthritis | Subsequent continuing treatment | 14499 | true | STREAMLINED | Any | 3,571 | 2,025 | FEBRUARY |
13315T | tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | juvenile idiopathic arthritis | Continuing treatment | 14179 | true | STREAMLINED | Private | 3,571 | 2,025 | FEBRUARY |
13724H | infliximab | Inflectra | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 3,571 | 2,025 | FEBRUARY |
13724H | infliximab | Renflexis | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 3,571 | 2,025 | FEBRUARY |
13724H | infliximab | Inflectra | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | true | AUTHORITY_REQUIRED | Private | 3,571 | 2,025 | FEBRUARY |
13724H | infliximab | Renflexis | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | true | AUTHORITY_REQUIRED | Private | 3,571 | 2,025 | FEBRUARY |
13724H | infliximab | Inflectra | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | true | AUTHORITY_REQUIRED | Private | 3,571 | 2,025 | FEBRUARY |